Clinical data on Fluarix®: An inactivated split seasonal influenza vaccine

Expert Review of Vaccines

Volumn 7, Issue 6, 2008, Pages 713-719

  El Sahly, Hana M ^a   Keitel, Wendy A ^a  

^a Division of Molecular Virology   (United States)

Author keywords

Fluarix ; Immunity; Influenza; Saftey; Vaccine

Indexed keywords

INFLUENZA VACCINE; PLACEBO;

CLINICAL TRIAL; DRUG INDICATION; DRUG SAFETY; FEVER; HIGH RISK POPULATION; HUMAN; IMMUNOGENICITY; INFECTION CONTROL; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; PRIORITY JOURNAL; REVIEW; SEROCONVERSION;

CLINICAL TRIALS AS TOPIC; EUROPE; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; UNITED STATES; VACCINES, INACTIVATED;

EID: 49449118351     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.6.713     Document Type: Review

References (55)

1. Crighton EJ, Moineddin R, Mamdani M, Upshur RE. Influenza and pneumonia hospitalizations in Ontario: a time-series analysis. Epidemiol. Infect. 132, 1167-1174 (2004).
2. Shek LP, Lee BW. Epidemiology and seasonality of respiratory tract virus infections in the tropics. Paediatr. Respir. Rev. 4, 105-111 (2003).
3. Eickhoff TC, Sherman IL, Serfling RE. Observations on excess mortality associated with epidemic influenza. JAMA 176, 776-782 (1961).
4. Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289, 179-186 (2003). •• Important article evaluating the excess mortality associated with influenza seasons in the USA.
5. Falsey AR, Hennessey PA, Formica MA, Cosx C, Walsh EE. Respiratory syncytial virus infection in elderly and high risk adults. N. Engl. J. Med. 352, 1749-1759 (2005).
6. Lui KJ, Kendal AP. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am. J. Public Health 77, 712-716 (1987).
7. Choi K, Thacker SB. Mortality during influenza epidemics in the United States, 1967-1978. Am. J. Public Health 72, 1280-1283 (1982).
8. Alling DW, Blackwelder WC, Stuart-Harris CH. A study of excess mortality during influenza epidemics in the United States, 1968-1976. Am. J. Epidemiol. 113, 30-43 (1981).
9. Simonsen L, Clarke MJ, Williamson D, Stroup DF, Arden NH, Schonberger LB. The impact of influenza epidemics on mortality: introducing a severity index. Am. J. Public Health 87, 1944-1950 (1997). •• Evaluates the excess mortality associated with influenza season and found that, in seasons when H3N2 strains predominate, mortality is worse.
10. Bhat N, Wright JG, Broder KR et al. Influenza-associated deaths among children in the United States, 2003-2004. N. Engl. J. Med. 353, 2559-2567 (2005).
11. Simonsen L, Clarke MJ, Schonberger LB, Arden NH, Cox NJ, Fukuda K. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J. Infect. Dis. 178, 53-60 (1998).
12. Simonsen L, Reichert TA, Viboud C, Blackwater WC, Taylro RJ, Miller MA. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch. Int. Med. 165, 265-72 (2005).
13. Wright PF, Ross KB, Thompson J, Karzon DT. Influenza A infections in young children: primary natural infection and protective efficacy of live vaccine-induced or naturally immunity. N. Engl. J. Med. 296, 829-834 (1977).
14. Glezen WP, Couch RB. Interpandemic influenza in the Houston area, 1974-76. N. Engl. J. Med. 298, 587-592 (1978). •• Pivotal study demonstrating the role of school-age children in the dissemination of influenza in a community.
15. Neuzil KM, Mellen BG, Wright PF, Mitchel EF, Griffin MR. The effects of influenza on hospitalizations, outpatient visits and courses of antibiotics in children. N. Engl. J. Med. 342, 225-231 (2000).
16. Izurieta HS, Thompson WW, Kramarz P et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N. Engl. J. Med. 342, 232-239 (2000).
17. Molinari NA, Ortega-Sanchez IR, Messonier ML et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 25, 5086-5096 (2007).
18. Demicheli V, Rivetti D, Deeks JJ, Jefferson TO. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst. Rev. 2, CD001269 (2007). •• Reviews the available literature on the efficacy and effectiveness of influenza vaccine in the young adults.
19. Rothberg MB, Rose DN. Vaccination versus treatment of influenza in working adults: a cost effectiveness analysis. Am. J. Med. 118, 68-77 (2005).
20. Bridges CB, Thompson WW, Meltzer MI et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults - a randomized controlled trial. JAMA 284, 1655-1663 (2000).
21. Belshe RB, Nichol KL, Black SB et al. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years. Clin. Infect. Dis. 39, 920-927 (2004).
22. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 272, 1661-1665 (1994). •• Randomized, placebo-controlled, evaluation of the efficacy of influenza vaccines in the elderly in The Netherlands.
23. Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 366, 1165-1174 (2005). •• Reviews the available literature on the efficacy and effectiveness of influenza vaccine in the elderly.
24. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N. Engl. J. Med. 357, 1373-1381 (2007).
25. Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect. Dis. 7, 658-666 (2007). •• Important discussion of the caveats of the available literature on the estimates of influenza vaccine effectiveness in the elderly.
26. Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int. J. Epidemiol. 35, 337-344 (2006).
27. Jefferson T, Smith S, Demicheli V, Hamden A, Rivetti A, Di Pietrantonj C. Assessment of the efficacy and effectivenss of influenza vaccines in healthy children: systematic review. Lancet 365, 773-780 (2005).
28. Monto AS, Davenport FM, Napier A, Francis T Jr. Effect of vaccination of a school-age population upon the course of an A2/Hong Kong influenza epidemic. Bull. World Health Organ. 41, 537-542 (1969).
29. Piedra PA, Gaglani MJ, Kozinetz CA et al. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine 23, 1540-1548 (2005).
30. Hurwitz ES, Haber M, Chang A et al. Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. JAMA 284, 1677-1682 (2000).
31. Glezen WP. Herd protection against influenza. J. Clin. Virol. 37, 237-243 (2006). •• Reviews the available data in favor of the concept of herd immunity following vaccination of children in a given community.
32. Fiore AE, Shay DK, Haber P et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm. Rep. 56, 1-54 (2007).
33. Treanor JJ, Campbell JD, Brady RC et al. Rapid licensure of a new, inactivated influenza vaccine in the United States. Hum. Vaccin. 1, 239-244 (2005).
34. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. 70, 767-777 (1972).
35. Treanor J, Wright PF. Immune correlates of protection against influenza in the human challenge model. Dev. Biol. 115, 97-104 (2003).
36. Hehme NW, Kunzel W, Petschke F et al. Ten years experience with the trivalent split-influenza vaccine, Fluarix. Clin. Drug Invest. 22, 751-769 (2002). •• Detailed description of the safety and immunogenicity data of registration trials of Fluarix® in Europe.
37. Beran J, Prymula R, Chlíbek R et al. Evaluation of reactogenicity and immunogenicity of two influenza vaccines (vaxigrip and fluarix) in the season 1996-1997. Cent. Eur. J. Public Health 6, 269-273 (1998).
38. Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on Harmonization of Requirements for Influenza Vaccines CPMP/BWP/214/96. The European Agency for the Evaluation of Medicinal Products, London, UK (1997).
39. Kanra G, Marchisio P, Feiterna-Sperling C et al. Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children. Pediatr. Infect. Dis. J. 23, 300-306 (2004).
40. Kanakoudi-Tsakalidou F, Trachana M, Pratsidou-Gertsi P, Tsitsami E, Kyriazopoulou-Dalaina V. Influenza vaccination in children with chronic rheumatic diseases and long-term immunosuppressive therapy. Clin. Exp. Rheumatol. 19, 589-594 (2001).
41. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24, 1159-1169 (2006).
42. Webster RG. Immunity to influenza in the elderly. Vaccine 18, 1686-1689 (2000).
43. Targonski PV, Jacobson RM, Poland GA. Immunosenescence: role and measurement in influenza vaccine response among the elderly. Vaccine 25, 3066-3069 (2007).
44. Ruf BR, Colberg K, Frick M, Preusche A. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Infection 32, 191-198 (2004).
45. Van Hoecke C, Prikazsky V, Utö I, Menschikowski C. Immunogenicity of an inactivated split influenza vaccine in institutionalized elderly patients. Gerontology 42, 190-198 (1996).
46. Brydak LB, Calbecka M. Immunogenicity of influenza vaccine in patients with hemato-oncological disorders. Leuk. Lymphoma 32, 369-374 (1999).
47. Burbach G, Bienzle U, Stark K et al. Influenza vaccination in liver transplant recipients. Transplantation 67, 753-755 (1999).
48. Brydak LB, Machala M, Laguna P, Rokicka-Milewska R. Antibody response to influenza vaccination in splenectomized patients in Poland. J. Clin. Immunol. 24, 225-236 (2004).
49. Cox MM. Progress on baculovirus-derived influenza vaccines. Curr. Opin. Mol. Therap. 10, 56-61 (2008).
50. Tosh PK, Poland GA. Emerging vaccines for influenza. Expert Opin. Emerg. Drugs 13, 21-40 (2008).
51. Ernst WA, Kim HJ, Tumpey TM et al. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 24, 5158-5168 (2006).
52. Epstein CL, Kong WP, Misplon JA et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23, 5404-5410 (2005).
53. Keitel WA, Atmar RL, Cate TR et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch. Intern. Med. 166, 1121-1127 (2006).
54. Update: influenza activity www.cdc.gov/mmwr/preview/mmwrhtml/mm57e215a1. htm (Accessed 28th February 2008)
55. US Centers for Disease Control and Prevention www.cdc.gov/od/oc/media/ pressrel/2008/r080227.htm (Accessed 25th March 2008)